Carlos E de Andrea

Country flagSpain

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (23)

Purpose: Intravenous dosing of the anti-CD137 (4-1BB) agonist monoclonal antibody urelumab is limited to 8 mg flat doses due to liver toxicity, thus reducing bioavailability. Here we explored intratumoral delivery of urelumab to increase bioavailability at the tumor, while reducing systemic exposure, in combination with systemic nivolumab (clinical trial INTRUST, NCT03792724). Patients and Methods: We delivered three 8 mg intratumoral injections of urelumab, alternating with intravenous nivolumab 240 mg every two weeks, followed by maintenance nivolumab at 480 mg every 4 weeks. Patients presenting solid tumors with known sensitivity to PD-1/PD-L1 blockade were treated in two cohorts (Cohort A: PD-1/PD-L1 blockade naive; Cohort B: progression following PD-1/PD-L1 blockade). The first six patients were treated in a safety dose-escalation cohort. We collected fresh tumor biopsies before the first three cycles and performed multiplex tissue immunofluorescence and bulk RNA-seq of these specimens. Additionally, we analyzed a comprehensive series of cytokines in sequential plasma samples. Results: Among 31 treated patients, we observed two objective responses and a 67.7% disease control rate. Treatment was well tolerated. Serial biopsies revealed urelumab-induced increases in T lymphocyte density and CD137 expression. The increase in tumor-infiltrating CD8 T cells was associated with durable clinical benefit. RNA-seq results were consistent with such pharmacodynamic changes. We observed significant plasmatic elevations of T-cell activation cytokines. Conclusions: Intratumoral delivery of urelumab is feasible, safe, and induces favorable immunopharmacodynamic effects in serial biopsies and in peripheral blood. Our results support the development of tumor-targeted next-generation CD137 (4-1BB) agonists.

Year:

2026

Tissue biomarker analyses and the VIGex score. A, Immune tumor contexture of the basal samples and surgical specimens in patients with MPR ( n = 8) and without MPR ( n = 25). B, Gene expression profile on surgical specimens, integrated within the VIGex score, and individual gene expression profile on surgical specimens. CK, cytokeratin; Post-ttm, posttreatment.

Year:

2025

Purpose: Immune checkpoint inhibitors combined with chemotherapy have provided successful results in patients with gastric and gastroesophageal junction (G/GEJ) cancers in the metastatic setting. Similar strategies have been explored in earlier stages. In this study, we present the final results of the phase II MONEO trial, which evaluated the addition of avelumab to neoadjuvant chemotherapy. Patients and Methods: Patients with untreated, resectable G/GEJ adenocarcinoma received neoadjuvant treatment with four cycles of avelumab plus the FLOT4 regimen, followed by surgery. Upon postoperative recovery, patients underwent four additional adjuvant cycles of the same combination, followed by avelumab monotherapy for up to 1 year. The primary endpoint was pathologic complete response rate. Sequential flow cytometry and cytokine determination were performed in peripheral blood, along with multiplex tissue immunofluorescence and RNA sequencing in tumor specimens. Results: Forty patients were enrolled, achieving a pathologic complete response rate of 21.1% (95% confidence interval, 10.0–37.0). The major pathologic response rate was 28.9%, more pronounced in patients with tumors expressing PD-L1 before treatment as measured by the combined positive score (cutoff, 10; 33.3% vs. 21.1%). The results propose several potential biomarkers considering tumor immune infiltrate, circulating immune cells, and cytokines. Eighty percent of patients experienced treatment-related grade ≥3 adverse events. Conclusions: The combination of avelumab plus the FLOT4 regimen showed relatively modest efficacy in resectable G/GEJ adenocarcinoma. Better results were observed in PD-L1 combined positive score ≥10% tumors. Exploratory biomarker analyses provide insights that may help to identify candidates most likely to benefit from chemoimmunotherapy as a neoadjuvant treatment.

Year:

2025

Analyses on circulating cytokines and leukocytes. A, Mean difference in peripheral cytokines (fold change) at cycle 1, cycle 2, and at presurgery evaluation between patients with MPR ( n = 11) and without MPR ( n = 25). B, Peripheral immune cells quantified as percentages and compared baseline and posttreatment results showing the difference between pCR ( n = 3) and non-pCR ( n = 8) patients, with the delta in patients with pCR as indicated. Positive (green) or negative (red) differences are color-coded, and the magnitude is reflected by the intensity of the color. MDSC, myeloid-derived suppressor cell; PBM, peripheral blood mononuclear; PMN, polymorphonuclear; TR/EG, regulatory T cells.

Year:

2025

Efficacy endpoints. A, Percentage of tumor regression grade. B, Tumor regression grade depending on PD-L1 CPS, HER2, and MMR status. C, PFS. D, OS. E, Subgroup analysis for PFS. F, Subgroup analysis for OS. pMMR, MMR-proficient.

Year:

2025

The precise mechanisms by which the complement system contributes to the establishment of an immunosuppressive tumor microenvironment and promotes tumor progression remain unclear. In this study, we investigated the expression and function of complement C5a receptor 1 (C5aR1) in human and mouse cancer-associated dendritic cells (DC). First, we observed an overexpression of C5aR1 in tumor-infiltrating DCs, compared with DCs from the blood or spleen. C5aR1 expression was restricted to type 2 conventional DCs and monocyte-derived DCs, which displayed a tolerogenic phenotype capable of inhibiting T-cell activation and promoting tumor growth. C5aR1 engagement in DCs drove their migration from tumors to tumor-draining lymph nodes, where C5a levels were higher. We used this knowledge to optimize an anticancer therapy aimed at enhancing DC activity. In three syngeneic tumor models, C5aR1 inhibition significantly enhanced the efficacy of poly I:C, a Toll-like receptor 3 agonist, in combination with PD-1/PD-L1 blockade. The contribution of C5aR1 inhibition to the antitumor activity of the combination treatment relied on type 1 conventional DCs and antigen-specific CD8 + T cells, required lymphocyte egress from secondary lymphoid organs, and was associated with an increase in IFNγ signaling. In conclusion, our study highlights the importance of the C5a/C5aR1 axis in the biology of cancer-associated DCs and provides compelling evidence for the therapeutic potential of modulating the complement system to enhance DC-mediated immune responses against tumors.

Year:

2025

IL12-based local gene therapy of cancer constitutes an active area of clinical research using plasmids, mRNAs, and viral vectors. To improve antitumor effects, we have experimentally tested the combination of mRNA constructs encoding IL12 and IL18. Moreover, we have used a form of IL18 [decoy-resistant IL18 (DR-18)] which has preserved bioactivity but does not bind to the IL18 binding protein decoy receptor. Both cytokines dramatically synergize to induce IFNγ release from mouse splenocytes, and, if systemically cotransferred to the liver, they mediate lethal toxicity. However, if given intratumorally to B16OVA tumor-bearing mice, the combination attains efficacy against the directly treated tumor and moderate tumor-delaying activity on distant noninjected lesions. Cotreatment was conducive to the presence of more activated CD8 + T cells in the treated and noninjected tumors. In keeping with these findings, the efficacy of treatment was contingent on the integrity of CD8 + T cells and cDC1 dendritic cells in the treated mice. Furthermore, efficacy of IL12 plus DR-18 local mRNA coinjection against distant concomitant tumors could be enhanced upon combination with anti–PD-1 mAb systemic treatment, thus defining a feasible synergistic immunotherapy strategy.

Year:

2025

The ability of conventional type-1 dendritic cells (cDC1) to cross-present tumor antigens to CD8 + T cells is critical for the induction of antitumor CTLs. Mice that are constitutively deficient in cDC1 cells have been reported to fail to respond to immunotherapy strategies based on checkpoint inhibitors. However, further work is needed to clarify the precise time during immunotherapy treatment that cDC1 cells are required for the beneficial effect of treatment. Here, we used a refined XCR1-DTR-Venus transgenic mouse model to acutely deplete cDC1 cells and trace their behavior using intravital microscopy. Diphtheria toxin–mediated cDC1 depletion prior to immunotherapy treatment with anti–PD-1 and/or anti-CD137 immunostimulatory mAbs completely ablated antitumor efficacy. The efficacy of adoptive T-cell therapy was also hampered by prior cDC1 depletion. After the onset of immunotherapy treatment, depletion of cDC1s only moderately reduced the therapeutic efficacy of anti–PD-1 and anti-CD137 mAbs. Intravital microscopy of liver-engrafted tumors revealed changes in the intratumoral behavior of cDC1 cells in mice receiving immunotherapy, and treatment with diphtheria toxin to deplete cDC1s impaired tumor T-cell infiltration and function. These results reveal that the functional integrity of the cDC1 compartment is required at the onset of various immunotherapies to successfully treat established tumors. Significance: These findings reveal the intratumoral behavior of cDC1 dendritic cells in transgenic mouse models and demonstrate that the efficacy of immunotherapy regimens is precluded by elimination of these cells.

Year:

2025

Supplementary Figure S4. Correlation between progression-free survival (PFS) and the dynamic alteration in the expression of additional soluble proteins in plasma samples. Samples were collected at baseline and week 13 (Cycle 3, day 1). PFS cut-off was defined as 7.2 months and calculated by MAXSTAT. Significance was defined as p

Year:

2024

Supplementary Figure S3. Dynamic modulation of soluble factors in paired plasma samples. Samples were collected at baseline and week 13 (Cycle 3, day 1). Significance was defined as p

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Collaborators (27)

Maria Carmen Ochoa

Associate researcher

Center for Applied Medical Research

SPAIN
View details

Javier Martinez-Trufero

Associated Proffesor

Universidad de Murcia Facultad de Medicina

SPAIN
View details

Mariano Ponz-Sarvise

Universidad de Navarra

SPAIN
View details

Javier Martín-Broto

-

SPAIN
View details

Alena Gros

Group Leader

Vall d'Hebron Institute of Oncology

SPAIN
View details

Pablo Sarobe

Investigador

-

SPAIN
View details

Trent Woodruff

Professor of Pharmacology

University of Queensland

AUSTRALIA
View details

Zuzana Ozaniak Strizova

Senior Researcher

University Hospital in Motol

CZECH REPUBLIC
View details

Pedro Berraondo

-

SPAIN
View details

Ana Vivancos

Principal Investigator

Vall d'Hebron Institute of Oncology

SPAIN
View details

Ruben Pio

Professor

Universidad de Navarra

SPAIN
View details

Belen Palencia

Clinica Universidad de Navarra

SPAIN
View details

John D. Lambris

University of Pennsylvania

UNITED STATES
View details

Beatriz Tavira

Research Associate

Universidad de Navarra

SPAIN
View details

Jose Maria Lopez-Picazo

Associate professor, accreditation required

Universidad de Navarra

SPAIN
View details

Ignacio Melero

Kidani Professor of Cancer Immuno-Therapeutics

University of Oxford

UNITED KINGDOM
View details

Alvaro Teijeira

Centro de Investigación Médica Aplicada, Universidad de Navarra

SPAIN
View details

Josep Tabernero

Associate Professor Faculty of Medicine

Universitat de Vic - Universitat Central de Catalunya

SPAIN
View details

Javier Burguete

Catedrático (Full Professor)

Universidad de Navarra

SPAIN
View details

Vladislav V. Verkhusha

University of Helsinki

FINLAND
View details

Guillermo Villacampa Javierre

Biostatistician

Vall d´Hebron Institute of Oncology

SPAIN
View details

Paula Jimenez-Fonseca

Central University Hospital of Asturias

SPAIN
View details

Dario Sangiolo

Associate Professor

University of Turin

ITALY
View details

Stefanie Wculek

Professor at IRB Barcelona

IRB Barcelona

SPAIN
View details

Giovanni Grignani

Director Sarcoma Unit

Candiolo Cancer Institute, FPO-IRCCS

ITALY
View details

Antonio González-Martín

Co-Director Medical Oncology Department

-

SPAIN
View details

Daniel Ajona

Assistant Professor

Universidad de Navarra

SPAIN
View details